Literature DB >> 9322979

Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats.

C V Lima1, R D Paula, F L Resende, M C Khosla, R A Santos.   

Abstract

In this study we evaluated the effect of angiotensin-(1-7) on the hypotensive action of bradykinin (BK) in normotensive rats, renal hypertensive rats (RHR), and spontaneously hypertensive rats (SHR). In addition, we evaluated the effect of angiotensin-converting enzyme (ACE) inhibition with enalaprilat treatment (10 mg/kg I.V.) on the BK-potentiating activity of Ang-(1-7). Renal hypertension was produced by aorta coarctation between the origin of renal arteries. Ang-(1-7) (0.3 pmol/min) or saline (0.9% NaCl, 5 microL/min) was infused intravenously in conscious male Wistar rats, adult SHR, or RHR. Intravenous bolus injections of BK (0.1 to 1.6 nmol in RHR and SHR; 0.625 to 5 nmol in Wistar rats) were made before and within 30 and 60 minutes of Ang-(1-7) infusion. Ang-(1-7) infusion did not change mean arterial pressure (MAP) of Wistar rats (MAP=97+/-3 mm Hg), RHR (MAP=173+/-3 mm Hg), or SHR (MAP=177+/-5 mm Hg). In Wistar rats, Ang-(1-7) increased the BK hypotensive effect by 24+/-6% within 60 minutes of infusion. No significant changes were observed at 30 minutes of infusion. In additional groups of rats, Ang-(1-7) (5 pmol/min, n=5) was infused alone or combined with its selective antagonist D-Ala7-Ang-(1-7) (A-779) (5 pmol/min, n=6). The bradykinin-potentiating activity of Ang-(1-7) was completely abolished by A-779. In SHR and RHR, Ang-(1-7) significantly increased the hypotensive effect of BK by 59+/-8% and 57+/-9.8%, respectively, within 60 minutes of infusion. No significant changes were observed with saline infusion. In Wistar rats, enalaprilat treatment increased the BK-potentiating activity of Ang-(1-7) transforming the effect of 0.3 pmol/min into that observed with a rate 16-fold higher (5 pmol/min). On the other hand, in SHR enalaprilat did not change the Ang-(1-7) effect, while it abolished the BK potentiation in RHR. Our data show that the BK-potentiating activity of Ang-(1-7) is preserved and even augmented in hypertensive rats. The finding that the BK-potentiating activity of Ang-(1-7) could be demonstrated at a very low infusion rate suggests that this angiotensin can act as an endogenous modulator of the vascular actions of kinins. ACE inhibition can influence differently the BK-potentiating activity of Ang-(1-7) in normotensive and hypertensive rats.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9322979     DOI: 10.1161/01.hyp.30.3.542

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  10 in total

1.  Angiotensin-converting enzyme inhibition, but not AT(1) receptor blockade, in the solitary tract nucleus improves baroreflex sensitivity in anesthetized transgenic hypertensive (mRen2)27 rats.

Authors:  Katsunori Isa; Amy C Arnold; Brian M Westwood; Mark C Chappell; Debra I Diz
Journal:  Hypertens Res       Date:  2011-09-22       Impact factor: 3.872

Review 2.  Angiotensin-(1-7) as an antihypertensive, antifibrotic target.

Authors:  Michael J Katovich; Justin L Grobe; Mohan K Raizada
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

3.  Analysis of erectile responses to bradykinin in the anesthetized rat.

Authors:  Justin A Edward; Edward A Pankey; Ryan C Jupiter; George F Lasker; Daniel Yoo; Vishwaradh G Reddy; Taylor C Peak; Insun Chong; Mark R Jones; Samuel V Feintech; Sarah H Lindsey; Philip J Kadowitz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-06-08       Impact factor: 4.733

4.  Angiotensin-(1-7) inhibits in vitro endothelial cell tube formation in human umbilical vein endothelial cells through the AT(1-7) receptor.

Authors:  Lauren Anton; David C Merrill; Liomar A A Neves; K Bridget Brosnihan
Journal:  Endocrine       Date:  2007-11-15       Impact factor: 3.633

Review 5.  Systemic and uteroplacental renin--angiotensin system in normal and pre-eclamptic pregnancies.

Authors:  Lauren Anton; K Bridget Brosnihan
Journal:  Ther Adv Cardiovasc Dis       Date:  2008-10

6.  New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis.

Authors:  Anderson J Ferreira; Tatiane M Murça; Rodrigo A Fraga-Silva; Carlos Henrique Castro; Mohan K Raizada; Robson A S Santos
Journal:  Int J Hypertens       Date:  2012-01-26       Impact factor: 2.420

Review 7.  Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension.

Authors:  Kwang Yong Shim; Young Woo Eom; Moon Young Kim; Seong Hee Kang; Soon Koo Baik
Journal:  Korean J Intern Med       Date:  2018-02-21       Impact factor: 2.884

Review 8.  Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets.

Authors:  Fan Jiang; Jianmin Yang; Yongtao Zhang; Mei Dong; Shuangxi Wang; Qunye Zhang; Fang Fang Liu; Kai Zhang; Cheng Zhang
Journal:  Nat Rev Cardiol       Date:  2014-04-29       Impact factor: 49.421

Review 9.  The sweeter side of ACE2: physiological evidence for a role in diabetes.

Authors:  Sharell M Bindom; Eric Lazartigues
Journal:  Mol Cell Endocrinol       Date:  2008-10-01       Impact factor: 4.102

Review 10.  Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy.

Authors:  Christoph Schindler; Peter Bramlage; Wilhelm Kirch; Carlos M Ferrario
Journal:  Vasc Health Risk Manag       Date:  2007
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.